Opinion statement
Patients with suspected or confirmed osteosarcoma should be evaluated and treated at a comprehensive cancer center within a multidisciplinary sarcoma program that includes pediatric, medical and radiation oncologists, orthopedic and surgical oncologists, musculoskeletal pathologists, and radiologists. Successful treatment involves proper diagnosis, neoadjuvant and adjuvant multi-agent chemotherapy, and aggressive surgery with an emphasis toward limb-preserving procedures. Treatment of osteosarcoma should be undertaken within the framework of large cooperative group clinical trials for children, adolescents, and adults. Patients treated with osteosarcoma should be followed closely both for recurrence of disease and for development of late effects of the treatment of their cancer. The treatment of metastatic, recurrent and/or refractory disease is more controversial. Despite advances in systemic treatment, surgical technique, and supportive care, the overall outcome is still poor.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Huvos, A. (1991) Bone Tumors: Diagnosis, Treatment Prognosis, 2nd Ed. WB Saunders, Philadelphia.
Gurney JG, Swensen AR, Bulterys M: Malignant bone tumors. In Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995. SEER program, National Cancer Institute, Bethesda, MD; 1999: 99–110
Link MP, Gebhardt MC, Meyers PA (2002) Osteosarcoma. In: Principles and Practice of Pediatric Oncology. Pizzo A, Poplack G. 4th Ed. Lippincott Williams and Wilkins, Philadelphia, 1051–89.
Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997; 44:973. doi:10.1016/S0031–3955(05)70540-X.
Ferrari S, Bacci G, Picci P et al. (1997) Long-term follow-up and post relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 8:765–00. doi:10.1023/A:1008221713505.
Thorpe WP, Reilly JJ, Rosenborg SA. (1979) Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43: 2178–2181. doi:10.1002/1097-0142(197906)43:6<2178::AID-CNCR2820430603>3.0.CO;2-9.
Kesselring FO, Penn W. Radiological aspects of “classic” primary osteosarcoma: value of some radiological investigations: a review. Diagn Imaging 1982, 51: 78–92.
McKillop JH, Etcubanas E, Goris ML. The indications for and limitations of bone scintigraphy in osteogenic sarcoma: a review of 55 patients. Cancer 1981, 46: 2603–2606.
McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005, 184: 1293–304.
Volker T, Denecke T, Steffen I, Misch D, Schonberger S, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007, 25: 5435–41. doi:10.1200/JCO.2007.12.2473.
Meyer JS, Nadel HR, Marina N, Womer RB, Brown KL, et al.: Imaging guidelines for children with ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008, 51: 163–170
Consensus guidelines from the Children’s Oncology Group Bone Tumor Committee for imaging children, adolescents and young adults with osteosarcoma and ewing sarcoma.
Hau A, Kim I, Kattapuram S, Hornicek FJ, et al. Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions. Skeletal Radiol 2002, 31: 349–53.
Peabody, TD, Simon MA. Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors. Orthop Clin North Am 1996, 27:453–9.
Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 1972, 4: 482–510.
Meyers P: Osteosarcoma. In Pediatric Bone and Soft Tissue Sarcomas. Edited by Pappo A. Berlin: Springer-Verlag; 2006; 219–233
Jaffe N, Frei E, Traggis D, et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974, 291: 994–997.
Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974, 291: 998–1000.
Gasparini M, Rouesse J, van Oosterom A, et al. Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer Treat Rep 1985, 69: 115–117.
Marti C, Kroner T, Remagen W, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 1985, 69: 115–117.
Goorin AM, Harris MB, Bernstein M, et al.: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002, 20: 426–433
A Pediatric Oncology Group study of etoposide and high-dose ifosfamide therapy in patients with metastatic osteosarcoma at diagnosis. Response rates and projected progression free survival was favorable compared to previous trials. However, long term data has not been reported.
Rosen G, Tan C, Sanmaneechai A, et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 1975, 35:936–945.
Rosen G, Marcove RC, Caparros et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979, 43: 2163–2177.
Goorin AM, Schwartzentruber DJ, Devidas M, et al.: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003, 21: 1574–1580
Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma group protocols. J Clin Oncol 2002, 20: 776
Very large series of patients from a multicenter database reviewing prognostic factors in high grade osteosarcoma.
Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988, 6: 329–337.
Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results and prognostic factors derived from a 10 year experience. J Clin Oncol 1990, 8: 1988–1997.
Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49; 1221–1230.
Bacci G, Picci P, Ferrari S et al. (1993) Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72: 3227–3238.
Saeter G, Alvegard TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T–10 protocol, with emphasis on the effects of pre-operative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group Study. J Clin Oncol 1991, 9: 1766–1775.
Provisor AJ, Ettinger LJ, Nachman JB et al. (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84.
Meyers PA, Schwartz CL, Krailo MD, et al.: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—A report from the Children’s Oncology Group. J Clin Oncol 2008, 26: 633–638
Large randomized trial of patients with localized osteosarcoma. Although a significant survival advantage was conferred with addition of MTP-PE, the study has been criticized for its analysis and interpretation of event free survival and overall survival.
Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma group’s protocol COSS–86 of the intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998, 9: 893–899.
Bacci G, Briccoli A, Ferrari A, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Canc 2001, 37: 2030–2039.
Lewis IJ, Nooij MA, Whelan J, et al.: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007, 99: 112–128
A large randomized trial comparing dose intensification with doxorubicin and cisplatin. Dose intensification significantly increased favorable histologic response though had no increase in event free survival or overall survival questioning histologic response as an outcome measure.
Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma groups. J Clin Oncol 2005, 23: 8845–8852
A joint study by the Italian and Scandinavian Sarcoma Groups exploring the effect of the addition of high-dose ifosfamide to standard therapy. There was no benefit of high-dose ifosfamide over standard dose ifosfamide.
Grimer R. Surgical options for children with osteosarcoma. Lancet: Oncology 2005, 6:85–92.
Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am, 1986; 68: 1331–37.
Gherlinzoni F, Picci P, Bacci G, et al.: Limb sparing versus amputation in osteosarcoma. Correlation between local control, surgical margins, and tumor necrosis: Istituto Rizzoli experience. Ann Oncol 1992; 3 (Suppl 2): S23–S27
Picci P, Sangiori L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 1997; 8:899–903.
Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27 year experience in a single institution. J Surg Oncol 2007, 96:118–23.
Wirganowicz PZ, Eckardt JJ, Dorey FJ, et al. Etiology and results of tumor endoprosthesis revision surgery in 64 patients. Clin Orthop Relat Res 1999; 358:64–74.
Torbert JT, Fox EJ, Hosalkar HS, et al. Endoprosthetic Reconstructions: results of long-term followup of 139 patients. Clin Orthop Relat Res 2005; 438:51–9.
Chao EY, Fuchs B, Rowland CM, et al. Long-term results of segmental prosthesis fixation by extracortical bone-bridging and ingrowth. J Bone Joint Surg Am 2004, 86:948–55.
Kramer MJ, Tanner BJ, Horvai AE, O’Donnell RJ. Compressive osseointegration promotes viable bone at the endoprosthetic interface: retrieval study of Compress implants. Int Orthop 2008, 32:567–71.
Eckardt JJ, Safran MR, Eilber FR, et al. Expandable endoprosthetic recontruction of the skeletally immature after malignant bone tumor resection. Clin Orthop Relat Res 1993, 297:188–202.
Neel MD, Wilkins RM, Rao BN, Kelly CM. Early multicenter experience with a non-invasive expandable prosthesis. Clin Orthop 2003, 415:72–81.
Rab GT, Ivins JC, Childs DS Jr, et al. Elective whole lung irradiation in the treatment of osteogenic sarcoma. Cancer 1976; 38: 939–942.
Breur K, Cohen P, Schweisguth O, et al. Irradiation of the lungs as an adjuvant therapy in the treatment of osteosarcoma of the limbs. An E.O.R.T.C. randomized study. Eur J Cancer 1978, 14: 461–471
Whelan JS, Burcombe RJ, Janinis J, et al. A systematic review of pulmonary irradiation in the management of primary bone tumours. Ann Oncol 2002, 13: 23–30.
Machak GN, Trachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high grade osteosarcoma of the extremities. Mayo Clinic Proc 2003, 78: 147–55.
Delaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Rad Onc Biol Phys 2005, 61: 492–98.
Delaney TF, Liebsch NJ, Pedlow FX, et al.: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009, 1–8 (in press)
Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium–153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002, 1: 189–96.
Bruland OS, Skretting A, Solheim OP, et al. Targeted radiotherapy of osteosarcoma using 153Sm-EDTMP. Acta Oncologica 1996, 35: 381–384.
Anderson PM, Nunez R. Samarium lexidronam (153Sm-EDTP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 2007, 7: 1517–27.
Harris MB, Gieser P, Goorin AM, et al. Treatment of metatastatic osteosarcoma at diagnosis: A Pediatric Oncology Group study. J Clin Oncol 1998, 16: 3641–3648.
Kager L, Zoubek A, Potschger U, et al.: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003, 21: 2011–2018
Large retrospective analysis of osteosarcoma patients presenting with metastasis treated on COSS group studies.
Thompson RC Jr, Cheng EY, Clohisy DR, et al. Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin Orthop Relat Res 2002, 397: 240–7.
Ferrari S, Bricolli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003, 21: 710–715.
Kempf-Bielack B, Bielack SS, Jurgens H, et al.: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Group (COSS). J Clin Oncol 2005, 20:559–568
Retrospective analysis of a large cohort of relapsed osteosarcoma patients. Time to relapse and tumor burden at relapse were correlated with survival.
Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy. The Memorial Sloan Kettering Cancer Center Experience. Cancer 2005, 104:2214–2221.
Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003, 98: 2447–2456.
Federman N, Feig SA. (2007) PET/CT in evaluating pediatric malignancies: a clinician’s perspective. J Nucl Med 48: 1923–31.
Bacci G, Ferrari C, Longhi A, et al. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol 2006, 28: 774–780.
Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center experience. Cancer 2002, 95: 1728–1734.
Goldsby R, Burke C, Nagarajan R, et al. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976. Cancer 2008, 113:2597–2604.
Van Dalen EC, Van der Pal HJ, Caron HN, Kremer LC (2006) Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochr Database Syst Rev 4:1–22.
Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochr Database Syst Rev 2008, 4: 1–44.
Longhi A, Macchiagodena M, Vitali G, Bacci G. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol 2003, 35: 292–296.
Stohr W, Paulides M, Bielack SS, et al.: Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 2007, 48: 140–147
Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and doetaxel in the treatment of children and young adults with bone sarcoma. Cancer 2008, 113: 419–25.
Muller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005, 44: 475–80.
Pritchard-Jones K, Spendlove I, Wilton C, et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer 2005, 92: 1358–1365.
Ullenhag GJ, Spendlove I, Watson NG, et al. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol 2008, 128: 148–154.
Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007, 67: 2800–2808.
Manetti F, Santucci A, Locatelli GA, et al. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem 2007, 50:5579–88.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Federman, N., Bernthal, N., Eilber, F.C. et al. The Multidisciplinary Management of Osteosarcoma. Curr. Treat. Options in Oncol. 10, 82–93 (2009). https://doi.org/10.1007/s11864-009-0087-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11864-009-0087-3